SlowMo therapy, a new digital blended therapy for fear of harm from others: An account of therapy personalisation within a targeted intervention.

blended therapy causal interventionism cognitive behavioural therapy digital human-centred design paranoia psychosis user-centred design

Journal

Psychology and psychotherapy
ISSN: 2044-8341
Titre abrégé: Psychol Psychother
Pays: England
ID NLM: 101135751

Informations de publication

Date de publication:
06 2022
Historique:
received: 08 05 2021
accepted: 06 12 2021
pubmed: 13 1 2022
medline: 14 5 2022
entrez: 12 1 2022
Statut: ppublish

Résumé

SlowMo therapy is a pioneering blended digital therapy for paranoia, augmenting face-to-face therapy with an interactive 'webapp' and a mobile app. A recent large-scale trial demonstrated small-moderate effects on paranoia alongside improvements in self-esteem, worry, well-being and quality of life. This paper provides a comprehensive account of therapy personalisation within this targeted approach. Case examples illustrate therapy delivery and descriptive data are presented on personalised thought content. Thought content was extracted from the webapp (n = 140 participants) and coded using newly devised categories: Worries: (1) Persecutory, (2) Negative social evaluation, (3) Negative self-concept, (4) Loss/life stresses, (5) Sensory-perceptual experiences and (6) Health anxieties. Safer thoughts: (1) Safer alternative (specific alternatives to worries), (2) Second-wave (generalised) coping, (3) Positive self-concept, (4) Positive activities and (5) Third-wave (mindfulness-based) coping. Data on therapy fidelity are also presented. Worries: 'Persecutory' (92.9% of people) and 'Negative social evaluation' (74.3%) were most common. 'General worries/ life stresses' (31.4%) and 'Negative self-concept' (22.1%) were present in a significant minority; 'Health anxieties' (10%) and 'Sensory-perceptual' (10%) were less common. Safer thoughts: 'Second-wave (general) coping' (85%), 'Safer alternatives' (76.4%), 'Positive self-concept' (65.7%) and 'Positive activities' (64.3%) were common with 'Third-wave' (mindfulness) coping observed for 30%. Fidelity: Only three therapy withdrawals were therapy related. Session adherence was excellent (mean = 15.2/16; SD = 0.9). Behavioural work was conducted with 71% of people (119/168). SlowMo therapy delivers a targeted yet personalised approach. Potential mechanisms of action extend beyond reasoning. Implications for cognitive models of paranoia and causal interventionist approaches are discussed.

Identifiants

pubmed: 35019210
doi: 10.1111/papt.12377
pmc: PMC9306634
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

423-446

Subventions

Organisme : National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London (Garety and Emsley)
ID : NIHR300051
Organisme : National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London (Garety and Emsley)
ID : NIHR-RP-2014-05-003
Organisme : NIHR Oxford Health Biomedical Research Centre
ID : BRC-1215-20005
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© 2021 The Authors. Psychology and Psychotherapy: Theory, Research and Practice published by John Wiley & Sons Ltd on behalf of The British Psychological Society.

Références

J Consult Clin Psychol. 2004 Aug;72(4):671-80
pubmed: 15301652
JAMA Psychiatry. 2021 Jul 1;78(7):714-725
pubmed: 33825827
Psychiatry Res. 2016 May 30;239:79-84
pubmed: 27137965
Philos Trans R Soc Lond B Biol Sci. 2018 Apr 19;373(1744):
pubmed: 29483352
Schizophr Res. 2014 Dec;160(1-3):186-92
pubmed: 25468186
Br J Psychiatry. 2005 May;186:427-35
pubmed: 15863749
Psychol Psychother. 2022 Jun;95(2):423-446
pubmed: 35019210
Br J Psychiatry. 2013 Jun;202:419-27
pubmed: 23661767
Philos Trans R Soc Lond B Biol Sci. 2018 Apr 19;373(1744):
pubmed: 29483354
J Ment Health. 2014 Aug;23(4):162-5
pubmed: 24433132
Br J Clin Psychol. 2002 Nov;41(Pt 4):331-47
pubmed: 12437789
JMIR Ment Health. 2018 Dec 05;5(4):e11222
pubmed: 30518514
Behav Res Ther. 2021 Mar;138:103803
pubmed: 33540242
Lancet Psychiatry. 2021 Mar;8(3):237-249
pubmed: 33485408
Psychol Med. 2015 Aug;45(11):2365-73
pubmed: 25805118
Psychol Med. 2013 Feb;43(2):269-77
pubmed: 22781166
J Behav Ther Exp Psychiatry. 2015 Sep;48:82-9
pubmed: 25770671
Psychol Med. 2001 Feb;31(2):189-95
pubmed: 11232907
Psychol Med. 2014 Oct;44(13):2729-38
pubmed: 25065271
Schizophr Bull. 2015 Mar;41(2):400-10
pubmed: 25053650
J Behav Ther Exp Psychiatry. 2011 Sep;42(3):414-21
pubmed: 21481815
Front Psychol. 2015 Oct 06;6:1450
pubmed: 26500570
Schizophr Bull. 2011 Mar;37(2):324-33
pubmed: 19520745
Schizophr Res. 2019 Jan;203:80-87
pubmed: 28927863
Lancet Psychiatry. 2015 Apr;2(4):305-13
pubmed: 26360083
Clin Psychol Rev. 2016 Jun;46:151-67
pubmed: 27216559
J Behav Ther Exp Psychiatry. 2017 Sep;56:144-151
pubmed: 27919404
Psychol Med. 2009 Jun;39(6):881-7
pubmed: 18845010
Schizophr Bull. 2020 Mar 27;:
pubmed: 32221536
Lancet Psychiatry. 2016 Jul;3(7):685-92
pubmed: 27371990
World Psychiatry. 2018 Oct;17(3):316-329
pubmed: 30192101
J Pers Soc Psychol. 1996 Aug;71(2):390-405
pubmed: 8765488
Lancet Psychiatry. 2021 Aug;8(8):696-707
pubmed: 34246324
Appl Ergon. 2015 Jan;46 Pt B:235-47
pubmed: 23570838
Am Psychol. 1994 Aug;49(8):709-24
pubmed: 8092614
Behav Res Ther. 2016 Feb;77:129-37
pubmed: 26752326
Schizophr Bull. 2016 May;42(3):652-65
pubmed: 26519952
Mol Psychiatry. 2012 Apr;17(4):377-88
pubmed: 22230881
J Abnorm Psychol. 2005 Aug;114(3):373-384
pubmed: 16117574
BMJ Open. 2017 Jul 17;7(7):e015297
pubmed: 28716789
Perspect Psychol Sci. 2013 May;8(3):223-41
pubmed: 26172965
Soc Psychiatry Psychiatr Epidemiol. 2014 Aug;49(8):1179-89
pubmed: 25005465
Psychol Med. 2007 Oct;37(10):1377-91
pubmed: 17335638
J Abnorm Psychol. 2012 Feb;121(1):129-139
pubmed: 21910515
Schizophr Bull. 2017 Mar 1;43(2):344-354
pubmed: 27169465
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571

Auteurs

Thomas Ward (T)

Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
South London and Maudsley NHS Foundation Trust, London, UK.

Amy Hardy (A)

Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
South London and Maudsley NHS Foundation Trust, London, UK.

Rebecca Holm (R)

Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Nicola Collett (N)

Department of Psychiatry, Oxford University, Oxford, UK.
Oxford Health NHS Foundation Trust, Oxford, UK.
Oxford Institute of Clinical Psychology Training and Research, Oxford University, Oxford, UK.

Mar Rus-Calafell (M)

Department of Psychiatry, Oxford University, Oxford, UK.
Oxford Health NHS Foundation Trust, Oxford, UK.
Mental Health Research and Treatment Center, Faculty of Psychology, Ruhr-Universität Bochum, Bochum, Germany.

Catarina Sacadura (C)

Sussex Partnership NHS Foundation Trust, Worthing, UK.

Alison McGourty (A)

Sussex Partnership NHS Foundation Trust, Worthing, UK.

Claire Vella (C)

Sussex Partnership NHS Foundation Trust, Worthing, UK.
School of Psychology, University of Sussex, Brighton, UK.

Anna East (A)

Department of Psychiatry, Oxford University, Oxford, UK.
Oxford Health NHS Foundation Trust, Oxford, UK.

Michaela Rea (M)

Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Helen Harding (H)

South London and Maudsley NHS Foundation Trust, London, UK.

Richard Emsley (R)

Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Kathryn Greenwood (K)

School of Psychology, University of Sussex, Brighton, UK.

Daniel Freeman (D)

Department of Psychiatry, Oxford University, Oxford, UK.
Oxford Health NHS Foundation Trust, Oxford, UK.

David Fowler (D)

Sussex Partnership NHS Foundation Trust, Worthing, UK.
School of Psychology, University of Sussex, Brighton, UK.

Elizabeth Kuipers (E)

Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Paul Bebbington (P)

Division of Psychiatry, University College London, London, UK.

Philippa Garety (P)

Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
South London and Maudsley NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH